Olfm4 (D6Y5A) XP® Rabbit mAb #39141
- WB
- IP
- IHC
- IF
Supporting Data
| REACTIVITY | M |
| SENSITIVITY | Endogenous |
| MW (kDa) | 85-90, 70 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- M-Mouse
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunohistochemistry (Paraffin) | 1:200 - 1:800 |
| Immunofluorescence (Frozen) | 1:200 - 1:800 |
Storage
For a carrier free (BSA and azide free) version of this product see product #25426.
Protocol
Specificity / Sensitivity
Olfm4 (D6Y5A) XP® Rabbit mAb recognizes endogenous levels of total mouse Olfm4 protein.
Species Reactivity:
Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala85 of mouse Olfm4 protein.
Background
Olfactomedin-4 (OLFM4, hGC-1) is a member of the Olfactomedin family, a small group of extracellular proteins defined by the presence of a conserved "Olfactomedin domain" that is thought to facilitate protein-protein interactions (1). OLFM4 is a secreted glycoprotein, which forms disulfide bond-mediated oligomers, and is thought to mediate cell adhesion through its interactions with extracellular matrix proteins such as lectins (2). Human OLFM4 was first cloned from myeloid cells (3) and is expressed in a distinct subset of neutrophils, though the functional significance of this differential expression pattern remains unclear (4). Among normal tissues, the expression of OLFM4 protein is most abundant in intestinal crypts (5), where it has garnered attention as a possible marker of intestinal stem cells (6). Notably, OLFM4 expression is markedly increased in several tumor types, including colorectal, gastric, pancreas, lung, and breast (reviewed in [1]). Furthermore, research studies show that the expression levels of OLFM4 vary in relation to the severity and/or differentiation status of multiple tumor types (1, 6-8), leading to the suggestion that OLFM4 may have utility as a prognostic marker in some cancer patients (9).
- Yu, L. et al. (2011) Neoplasma 58, 9-13.
- Liu, W. et al. (2006) Exp Cell Res 312, 1785-97.
- Zhang, J. et al. (2002) Gene 283, 83-93.
- Welin, A. et al. (2013) PLoS One 8, e69575.
- van der Flier, L.G. et al. (2009) Gastroenterology 137, 15-7.
- Liu, W. et al. (2007) Histopathology 51, 157-65.
- Liu, W. et al. (2008) Clin Cancer Res 14, 1041-9.
- Besson, D. et al. (2011) Mol Cell Proteomics 10, M111.009712.
- Seko, N. et al. (2010) Exp Ther Med 1, 73-8.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.